The current financial score of Biogen Inc is 8.87. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 2.74B, representing a year-over-year increase of 3.42%, while its net profit experienced a year-over-year increase of 84.64%.
The current valuation score of Biogen Inc is 9.57. Its current P/E ratio is 26.81, which is 24.43% below the recent high of 33.36 and 100.00% above the recent low of 0.00.
The current earnings forecast score of Biogen Inc is 7.79. The average price target is 244.87, with a high of 310.00 and a low of 175.00.
The current price momentum score of Biogen Inc is 4.07. Currently, the stock price is trading between the resistance level at 264.82 and the support level at 226.14, making it suitable for range-bound swing trading.
The current institutional shareholding score of Biogen Inc is 10.00. The latest institutional shareholding proportion is 98.05%, representing a quarter-over-quarter increase of 0.24%.
The current risk assessment score of Biogen Inc is 8.91. The company's beta value is 0.20. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.